Interleukin 7 receptor activates PI3K/Akt/mTOR signaling pathway via downregulation of Beclin-1 in lung cancer
- PMID: 30362635
- DOI: 10.1002/mc.22933
Interleukin 7 receptor activates PI3K/Akt/mTOR signaling pathway via downregulation of Beclin-1 in lung cancer
Abstract
Interleukin-7(IL-7) can regulate proliferation and apoptosis of cell and also regulate tumor lymphangiogenesis, but whether it regulating autophagy of tumor cells is not well known. We study the relationship between IL-7 and some autophagy-related markers, Beclin 1 and mammalian target of rapamycin (mTOR) and the mechanism of IL-7 in regulating autophagy of human lung cancer cells. We detected expression of Beclin 1 and mTOR in lung cancer cells and their impact on the prognosis of lung cancer patients. Using Western blot and Reverse Transcription PCR, we found that IL-7 activates PI3 K/Akt/mTOR signaling pathway by downregulated the expression of Beclin 1 in lung cancer cell lines. In addition, the expressions of Beclin 1 and mTOR were well correlated with clinical stages and survival of human non-small cell lung cancer (NSCLC) patients. IL-7R, mTOR, and tumor stage were the independent prognosticators in lung cancer. Taken together, our results provided evidence that IL-7 activates PI3 K/Akt/mTOR signaling pathway via Beclin 1 to regulate autophagy in lung cancer cells.
Keywords: Beclin 1; Interleukin-7 Receptor; Interleukin7; lung cancer; mTOR.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.Oncol Rep. 2018 Oct;40(4):2353-2362. doi: 10.3892/or.2018.6583. Epub 2018 Jul 20. Oncol Rep. 2018. PMID: 30066933
-
Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10644-52. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26617774 Free PMC article.
-
Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non‑small cell lung cancer.Oncol Rep. 2018 Oct;40(4):1971-1984. doi: 10.3892/or.2018.6634. Epub 2018 Aug 7. Oncol Rep. 2018. PMID: 30106450 Free PMC article.
-
[PI3K/Akt/mTOR signaling pathway and non-small cell lung cancer].Zhongguo Fei Ai Za Zhi. 2010 Dec;13(12):1149-54. doi: 10.3779/j.issn.1009-3419.2010.12.13. Zhongguo Fei Ai Za Zhi. 2010. PMID: 21159253 Free PMC article. Review. Chinese.
-
Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC).Thorac Cancer. 2020 Mar;11(3):511-518. doi: 10.1111/1759-7714.13328. Epub 2020 Jan 27. Thorac Cancer. 2020. PMID: 31989769 Free PMC article. Review.
Cited by
-
Roles of IL-7R Induced by Interactions between Cancer Cells and Macrophages in the Progression of Esophageal Squamous Cell Carcinoma.Cancers (Basel). 2023 Jan 6;15(2):394. doi: 10.3390/cancers15020394. Cancers (Basel). 2023. PMID: 36672342 Free PMC article.
-
The role of interaction between autophagy and apoptosis in tumorigenesis (Review).Oncol Rep. 2022 Dec;48(6):208. doi: 10.3892/or.2022.8423. Epub 2022 Oct 12. Oncol Rep. 2022. PMID: 36222296 Free PMC article. Review.
-
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).J Clin Oncol. 2023 Jan 20;41(3):651-663. doi: 10.1200/JCO.22.00727. Epub 2022 Oct 7. J Clin Oncol. 2023. PMID: 36206498 Free PMC article. Clinical Trial.
-
Comprehensive analysis of tissue proteomics in patients with papillary thyroid microcarcinoma uncovers the underlying mechanism of lymph node metastasis and its significant sex disparities.Front Oncol. 2022 Aug 29;12:887977. doi: 10.3389/fonc.2022.887977. eCollection 2022. Front Oncol. 2022. PMID: 36106120 Free PMC article.
-
Interleukin-7 regulates CD127 expression and promotes CD8+ T cell activity in patients with primary cutaneous melanoma.BMC Immunol. 2022 Jul 18;23(1):35. doi: 10.1186/s12865-022-00509-0. BMC Immunol. 2022. PMID: 35850640 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
